Why the study?
Does propranolol therapy improve outcomes in an infant with hypertrophic obstructive cardiomyopathy?
Does propranolol therapy improve outcomes in an infant with hypertrophic obstructive cardiomyopathy?
This case report provides the first evidence of propranolol use in an infant with hypertrophic obstructive cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Infantile HOCM propranolol use remains unproven by this case; leaves open need for controlled trials before adoption.
ALTHOUGH the beta-adrenergic blocking drug, propranolol, has been used in adults with hypertrophic obstructive cardiomyopathy,1 2 3 its use in children has not yet been reported. The youngest child in whom the diagnosis has been confirmed was one year of age,4 and operative correction was unsuccessful. The eight-week-old child described below had a three-year follow-up of propranolol treatment. Because there was no information on pediatric dosage, therapy was monitored by measurements of plasma levels of the drug.Case ReportThis infant with no relevant past or family history was delivered normally at full-term weighing 3.7 kg. She failed to thrive and weighed . . .
No takes yet. Share an insight, caveat, or question.
Shand et al. (1971) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: